News

Filter

Current filters:

Biogen Idecdaclizumab

1 to 9 of 20 results

New entrants to multiple sclerosis market will drive 10% pa growth through 2018

26-07-2013

The market for disease-modifying multiple sclerosis (MS) therapies will expand at an annual rate of 10%…

AbbVieAubagioBayerBiogen IdecBiotechnologydaclizumabGlobalLemtradaMarkets & MarketingNeurologicalocrelizumabPharmaceuticalRocheSanofiTecfidera

Biogen jumps on strong MS drug data: Sanofi’s Lemtrada significant improvement on Rebif

24-10-2011

US biotech firm Biogen Idec (Nasdaq: BIIB) saw its shares jump 6% to $107.53 last Friday, after the company…

AlemtuzumabBiogen IdecBiotechnologydaclizumabdimethyl fumarateGenzymeLemtradaNeurologicalPharmaceuticalResearchSanofi

Biogen Idec and Abbott MS drug candidate daclizumab positive in Ph IIb

10-08-2011

US biotech Biogen Idec (Nasdaq: BIIB) and health care giant Abbott Laboratories (NYSE: ABT ) have announced…

Abbott LaboratoriesBiogen IdecBiotechnologydaclizumabNeurologicalPharmaceuticalResearch

Facet Biotech Stockholders reject Biogen Idec tender offer, so deal over

18-12-2009

USA-based Biogen Idec’s fight to gain control of Facet Biotech came to an end last night, when the…

Biogen IdecBiotechnologydaclizumabMergers & AcquisitionsNeurologicalNorth AmericaOncologyPharmaceuticalZenapax

Biogen Idec ups offer 21% for Facet Biotech to $17.50 a share, which is again rejected by board

04-12-2009

December 4, 2009 US biotechnology firm Biogen Idec is continuing its fight to gain control of Facet…

Biogen IdecBiotechnologydaclizumabMergers & AcquisitionsNeurologicalNorth AmericaOncologyPharmaceuticalZenapax

Facet Biotech says Biogen Idec’s offer undervalues the firm

09-09-2009

Facet Biotech’s board of directors has reviewed Biogen Idec's unsolicited acquisition offer, made…

Biogen IdecdaclizumabNeurologicalNorth AmericaPharmaceuticalZenapax

Facet Biotech confirms hostile bid from Biogen Idec

07-09-2009

Facet Biotech Corp has confirmed that it is in receipt of fellow USA-based Biogen Idec

Biogen IdecBiotechnologydaclizumabNeurologicalNorth AmericaOncologyZenapax

1 to 9 of 20 results

COMPANY SPOTLIGHT

Menarini

Back to top